Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Completed · Phase 4

Conditions studied: Atherosclerosis, Hypercholesterolemia

In brief

Background: \- Atherosclerosis (thickening of the artery walls caused by cholesterol and other deposits) commonly occurs in the heart vessels and carotid (neck) arteries of adults. This is often present in individuals with high cholesterol levels in their blood. These patients are usually treated with cholesterol lowering medication ( statins ) along with modification of diet and exercise. Researchers are interested in investigating new approaches including magnetic resonance imaging (MRI) and computed tomography (CT) imaging studies to detect blood vessel blockages that would not otherwise be detected by cholesterol levels and risk factors for heart disease. Objectives: \- To measure atherosclerosis in the heart vessels and carotid arteries using imaging tests (computed tomography (CT) and magnetic resonance imaging (MRI)) before and after standard treatment with cholesterol lowering medication ( statins ) Eligibility: \- Healthy individuals at least 55 years of age who are candidates for therapy to lower their blood cholesterol levels. Design: * This study will involve one screening visit and seven study visits over a period of 2 years. * Participants will be screened with a physical examination and medical history, as well as blood samples and tests to ensure that it is safe for them to have CT and MRI scans. Participants will provide information on current medications, dietary habits, smoking status, alcohol and caffeine intake, and their level of physical activity. * Participants will be divided into two groups. One group will receive standard doses of medication to lower cholesterol according to current treatment guidelines, while the other group will have MRI scans of the carotid arteries and a CT scan of the heart to determine the best medication dose levels. * Visits 3 to 5 will be scheduled 3, 6, and 9 months after visit 2. During these visits, researchers will monitor for possible side effects and may change or adjust medications and doses. * At visit 6, participants will have an MRI scan of the carotid arteries, a physical examination, and blood tests. Medications may be changed or adjusted. * At visit 7, participants will have blood tests, and medications may be changed or adjusted. * At the final visit, participants will have MRI and CT scans of the carotid arteries and heart, respectively, as well as a final physical examination and blood tests.

Key facts

Study ID

NCT01212900

Run by

National Heart, Lung, and Blood Institute (NHLBI)

People needed

230

Starts

2010-09-30

Expected to finish

2017-02-22

Last updated by the study team

2018-11-30

Who can join

Age: 50 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• A. Ineligibility for MR imaging due to:
• Previous pacemaker implantation
• Automatic implantable cardioverter-defibrillator (AICD)
• Metal implants or other ferromagnetic devices, or
• Foreign material
• B. Claustrophobia
• C. Contra-indication or allergy to statin medications.
• D. Current statin therapy at or above the maximum dosage permitted per study protocol.
• E. Use of fibrates, ezetimibe, niacin, or bile acid binding agents within 6 months of screening visit.
• F. Pregnancy and nursing.
• G. Liver failure defined clinically and by laboratory data.
• H. Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial.
• I. Any other conditions that precludes safety for MRI and/or CT imaging per the researcher s evaluation.
• EXCLUSION FOR PARTICIPATION FOR GADOLINUIM CONTRAST. PARTICIPANTS MAY STILL UNDERGO ALL OTHER STUDY EVALUATIONS.
• (Inclusive of the above exclusion criteria):
• Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.
• Acute renal failure, renal transplant, dialysis and renal failure (eGFR < 45 mL/min/m2 and/or clinically diagnosed).
• Individuals with a history of liver transplant or severe liver disease.<TAB>
• Individuals with hemoglobinopathies or severe asthma.
• EXCLUSION FOR PARTICIPATION FOR IODINATED CONTRAST. PARTICIPANTS MAY STILL UNDERGO ALL OTHER SUDY EVALUATIONS.
• Prior hypersensitivity reaction to iodinated contrast injection, renal dysfunction (defined as eGFR < 45 mL/min/ m2) or a current clinical diagnosis of renal failure.
• EXCLUSION CRITERIA FOR THE PET SUBSTUDY:
• Patients who are unable or unwilling to comply with the physical activity restrictions or fast for 12 hours prior to FDG PET scanning will be excluded. Due to the need for dietary manipulation and the maintenance of strict glycemic control we will exclude diabetic patients from our initial study sample. Blood glucose measurements before injection must be within normal limits, less than 200 mg/dL (11 mmol/L).
• EXCLUSION CRITERIA FOR THE REPRODUCIBILITY
• Patients who did not have a one RR interval initial CT scan. Patients who will participate in the PET Substudy.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.